18 results about "Vitreous cavity" patented technology

In certain embodiments, an ophthalmic system is provided. The ophthalmic system includes a low power laser source configured to generate a low power laser beam, wherein the low power laser source has a power of between 5 milliwatts (mW) and 20 mW, and a first illumination device configured to transmit the low power laser beam into a vitreous cavity of an eye. The ophthalmic system further includes a red-green-blue (RGB) light-emitting diode (LED) light source configured to generate a RGB light, and a second illumination device configured to transmit the RGB light into the vitreous cavity of the eye.

The application discloses a diopter-adjustable and real-time retina imaging detection simulation eye, comprising: an emulated cornea, an emulated lens and an adjustable vitreous structure arranged in sequence along an optical axis; the adjustable vitreous structure comprises: a vitreous cavity filled with an emulated vitreous, a curved retina arranged at the end of the vitreous cavity, and a micrometer adjustment system for driving the curved retina to move forward and backward along the optical axis; the foveal region of the curved retina is integrated with an attenuation module and an imaging module, which are used for collecting a light spot image on the foveal region in real time; the simulation eye further comprises an analysis module electrically connected with the imaging module, and the analysis module is configured to process the collected light spot image to extract optical parameters on the curved retina.

This invention discloses a spring-loaded intraocular syringe based on intraocular pressure feedback, belonging to the field of medical devices. The core improvement of this device lies in the integration of an integrated spring mechanism at the syringe outlet interface. Its main structure is a hollow cylindrical structure forming a three-way connection with the syringe outlet interface. A sealing septum divides the inner cavity of the main structure into a non-communicating medication chamber and a spring chamber. During injection, the intraocular pressure is transmitted to the sealing septum through the medication. When the pressure exceeds the spring's preset preload, the spring is compressed, causing the sealing septum to displace. When this displacement reaches a preset safe intraocular pressure threshold, it triggers a visually intuitive stop signal, objectively and accurately prompting the operator to stop the injection. This invention achieves automatic matching control of the injection volume and intraocular pressure through a mechanical pressure feedback mechanism, reducing reliance on operator experience and improving the safety and precision of surgical procedures, making it particularly suitable for primary healthcare settings.

An ophthalmic assembly includes a frame, a flange, and a light emitter. The frame supports the optical lens. A first end of the flange is connected to the frame. The second end of the flange rests on a ciliary body flat region of the sclera of the patient's eye. A light emitter is connected to the flange proximate the second end to direct light into a vitreous cavity of the patient's eye. Light passes through the sclera at the flat region of the ciliary body, uniformly illuminating the vitreous body. A transscleral illumination system includes the ophthalmic assembly and a processor in communication with the light emitter. The setting of the light emitter may be controlled via a processor, for example in response to a user input signal.

The invention discloses a vitreous cavity medicine injection center scheduling method and system based on hybrid reinforcement learning and a storage medium. The method mainly solves the problems of slow convergence, low exploration efficiency and the like when a traditional scheduling method is used for processing a high-dimensional state space, sparse reward signals and multi-target conflicts. The method has the beneficial effects that the scheduling efficiency is remarkably improved: in a simulation environment, the average waiting time of patients can be shortened by more than 20%, and the treatment room turnover rate is improved by more than 15%; the system is high in adaptability: through a hybrid reinforcement learning architecture, patient flow change and resource state fluctuation can be dynamically responded, and long-term steady-state optimization is realized; multi-objective collaborative optimization: efficiency, fairness and medical safety are effectively balanced through multi-objective reward function design and constraint embedding; and the system provides a decision explanation mechanism, so that the sense of trust and the use intention of medical staff to the intelligent scheduling scheme are enhanced.

The present application relates to a kind of lens puncture fixing devices, lens puncture fixing device includes outer tube unit, inner core unit, claw unit, inner core control unit and claw control unit, or, lens puncture fixing device includes outer tube unit, inner core unit, claw unit and claw control unit, or, lens puncture fixing device includes outer tube unit, inner core unit, claw unit and outer tube control unit.Its advantages are, by the relative motion of outer tube unit and inner core unit, realize puncture function, by the relative motion of claw unit and inner core unit, realize clamping fixed function, dislocation lens is fixed in pupil area, reduce the excessive cortex or nuclear fragment falling into vitreous cavity in the process of resection by vitrectomy head;Puncture function and clamping fixed function are integrated and arranged, realize two-stage fixed mode using one instrument, reduce operation difficulty.

The invention discloses application of oroxylum indicum total flavonoids in preparation of a medicine for treating uveitis. Experiments prove that the eye drops taking the oroxylum indicum total flavonoids or the oroxylin A as the active ingredient can reduce the uveitis eye inflammation and retina injury degree and reduce the infiltration quantity of inflammatory cells. The oroxylum indicum general flavone is taken as an oral medicine, so that inflammatory infiltration cells of a vitreous cavity and an iris-ciliary body can be reduced, bleeding symptoms can be effectively improved, hyperplasia of iris-ciliary body tissues can be inhibited, and infiltration of leukocytes of aqueous humor in mouse eyes can be effectively inhibited.

An illumination system includes a light source configured to generate light having a first optical property and a transscleral illumination device configured to transmit light having the first optical property across a sclera and into a vitreous cavity of an eye. A sensor is configured to detect light in the vitreous cavity of the eye as having a second optical property. The sensor generates a first signal indicative of the second optical property. One or more processors receive the first signal and cause the light source to generate light having a third optical property based on a the first signal. The sensor detects light in the vitreous cavity of the eye as having an optical property that is at least within a threshold of the first optical property. The sensor generates a second signal indicative of the first optical property.

The invention provides an injection gas pressure maintaining injector in a vitreous cavity gas injection operation, and relates to the technical field of ophthalmologic operation instruments, the injection gas pressure maintaining injector comprises a main body, a first chamber and a second chamber which are separated by a partition plate are arranged in the main body, and an elastic sealing plug is arranged on the partition plate. During air intake, the piston is pulled backwards, and the sealing plug blocks the vent hole; during air outlet, the air inlet is closed, the piston is pushed forwards, and the sealing plug is pressed to deform to conduct airflow. After pushing injection is finished and pressure is removed, the sealing plug is automatically reset and locked, and gas backflow is prevented. The one-way valve function is achieved through a pure mechanical structure by means of the air pressure difference, thrust does not need to be kept all the time, the problems of gas backflow and retina restoration failure caused by the fact that a common injector cannot achieve automatic pressure maintaining are thoroughly solved, and the success rate of an operation can be effectively guaranteed.

The invention relates to the technical field of biological medicine, in particular to sophocarpine and application of sophocarpine in inhibiting formation of subretinal fibrosis, and the sophocarpine comprises the following steps: selecting 7-week-old male C57BL / 6J mice, adaptively feeding the mice for 1 week, and performing 12-hour illumination / 12-hour dark circulation at the environment temperature of 22-25 DEG C; the method comprises the following steps of: performing intraperitoneal injection of thiobarbital sodium on a C57 mouse fed for 1 week for anesthesia, realizing muscle relaxation by using hypnotic, and anesthetizing ocular surface by using 0.4% tetracaine and 0.5% tropicamide mydriasis; a mouse is randomly divided into a control eye and an experiment eye, and 1 microliter of PBS containing 1.5% of DMSO is injected into the control eye to serve as a carrier for control. The invention finds that injection of sophocarpine in vitreous cavity can inhibit RPE cell epithelial-mesenchymal transition, can be used for preventing or treating age-related macular degeneration subretinal fibrosis, may become a new medicine for treating subretinal fibrosis, has important value for inhibiting EMT of RPE cells, can also inhibit EMT of other cells, and can be used for preventing or treating age-related macular degeneration subretinal fibrosis and treating age-related macular degeneration subretinal fibrosis. Therefore, the method has potential application value on diseases caused by cell EMT.

The application provides an intraocular vitreous cavity foreign body optical fiber net bag, and relates to the technical field of medical devices, which comprises an outer sheath, a positioning block fixedly connected to one side of the outer sheath, a collecting assembly arranged on one side of the outer sheath, the collecting assembly comprising a shaping wire a, an arc-shaped shaping wire a, a shaping wire b, an arc-shaped shaping wire b and a net bag, and an optical fiber probe, and a pulling hole is formed in the inner part of the outer sheath. The foreign body optical fiber net bag can realize automatic tightening of the net bag opening through the arrangement of the collecting assembly, ensure the stability of foreign body capture, realize a two-handed cooperation mode of left-hand holding of the net bag and right-hand holding of a vitreous cutting head, improve the safety of surgery, and realize locking and quick release of the position of the net bag through the arrangement of a limiting assembly, cooperate with the elastic reset function of a small spring, and enhance the convenience and reliability of the operation of the device.

An illumination system includes a light source configured to generate light having a first optical property and a transscleral illumination device configured to transmit light having the first optical property across a sclera and into a vitreous cavity of an eye. A sensor is configured to detect light in the vitreous cavity of the eye as having a second optical property. The sensor generates a first signal indicative of the second optical property. One or more processors receive the first signal and cause the light source to generate light having a third optical property based on a the first signal. The sensor detects light in the vitreous cavity of the eye as having an optical property that is at least within a threshold of the first optical property. The sensor generates a second signal indicative of the first optical property.

A shunt 200 for treating glaucoma in a patient during and / or after vitreoretinal surgery involving the use of a tamponading agent comprising a gas or oil bubble 50. The shunt includes a tubular body 12 having a proximal end 14 which is implantable in the vitreous cavity C of a patient and a distal end which is implantable in the subarachnoid space of the patient. The tubular body defines a lumen 18 extending between the distal and proximal ends. The shunt includes an occlusion body 32 defining a number of micro-passages 34 inflow communication with the lumen 18. The micro-passages are configured in terms of their size and number to provide sufficient surface tension and viscosity resistance in order to prevent the tamponading agent from passing through the micro-passages into the lumen, yet allow sufficient aqueous fluid from the vitreous cavity to travel along the micro-passages into the lumen 18 in order to regulate intraocular pressure.

The invention relates to a lens puncture fixing device. The lens puncture fixing device comprises an outer tube unit, an inner core unit, a claw unit and an outer tube control unit. The intraocular lens puncture device has the advantages that the puncture function is achieved through relative movement of the outer tube unit and the inner core unit, the clamping and fixing function is achieved through relative movement of the claw unit and the inner core unit, a dislocated crystalline lens is fixed to a pupil area, and the situation that excessive cortex or nucleus fragments fall into a vitreous cavity in the excision process of a vitreous head is reduced; the puncture function and the clamping and fixing function are integrated, a double-stage fixing mode is achieved through one instrument, and the operation difficulty is lowered.

In certain embodiments, an ophthalmic system is provided. The ophthalmic system includes a low power laser source configured to generate a low power laser beam, wherein the low power laser source has a power of between 5 milliwatts (mW) and 20 mW, and a first illumination device configured to transmit the low power laser beam into a vitreous cavity of an eye. The ophthalmic system further includes a red-green-blue (RGB) light-emitting diode (LED) light source configured to generate a RGB light, and a second illumination device configured to transmit the RGB light into the vitreous cavity of the eye.

The application discloses a silicone oil filling simulation method and device for assisting treatment of retinal detachment, and the method comprises the following steps: constructing an eyeball wall model of a patient according to an elastic solid modeling method, and maintaining the incompressibility of the eyeball wall by adopting an implicit iterative correction pressure method based on the number density; for the scene of filling silicone oil in the intraocular cavity during surgery, the silicone oil is regarded as a high-viscosity incompressible Newton fluid, and the interaction between the silicone oil and the eyeball wall is simulated according to the coupling method between the fluid and the elastic solid; and the three-phase coupling environment composed of water, silicone oil and the eyeball wall generated by the aqueous humor entering the vitreous cavity after surgery is simulated, and the emulsification phenomenon of the water and the silicone oil occurring at the immiscible boundary is simulated. According to the technical scheme of the application, the eyeball wall is constructed according to the elastic solid modeling method, the filling environment is visualized, and the dynamic interaction generated by the filling is simulated through the volume incompressible model based on the number density, so that accurate quantitative analysis can be provided for the surgical treatment.

The invention relates to the technical field of biological medicine, in particular to a self-anchored sustained-release drug vitreous cavity implantation device. The technical problem that an existing slow release system is difficult to cooperate in the aspects of positioning stability, release controllability and in-vivo clearance is solved. The flexible drug delivery system comprises a flexible drug storage cavern, an anchoring-valve integrated structure, a microfluidic valve and a drug release channel, the anchoring arm is unfolded to penetrate into the vitreous body matrix to realize self-anchoring, and synchronously drives the extrusion column to compress the storage cavern, so that the internal pressure is increased, the micro-fluidic valve is opened, and drug release is started; along with the hydrolysis of the degradable material, the anchoring force and the extrusion force gradually disappear, and the drug release is naturally terminated. The device does not need an external energy source, realizes release starting when in place and self-destruction after release, and has the characteristics of precise drug release and complete biological absorbability.

The invention relates to the field of medicine, namely to ophthalmology, and can be used in the combined treatment of active retinopathy of prematurity type 1 in zone 1, in children with a gestational age of less than 28 weeks. The technical objective is to develop an effective method for the combined treatment of active retinopathy of prematurity type 1 in zone 1, in children with a gestational age of less than 28 weeks, by performing simultaneous transpupillary laser coagulation of the retina only in the nasal quadrants and introducing an angiogenesis inhibitor into the vitreous cavity. The proposed method solves this problem, involving simultaneous transpupillary laser photocoagulation of avascular zones of the retina in the nasal quadrants only and the injection of an angiogenesis inhibitor into the vitreous cavity. This method prevents the development of tractional retinal detachment, which causes blindness and low vision in children, reactivation of active ROP, and postoperative uveitis, which require additional surgical treatment, in 100% of cases.